Welcome to the first European Bank for induced pluripotent Stem Cells (EBiSC)
|
EBiSC has been designed to address the increasing demand for quality-controlled, disease-relevant, research-grade iPSC lines, data and cell services. EBiSC is a centralised, not-for-profit iPSC bank providing researchers across academia and industry with access to scalable, cost-efficient and consistent, high quality tools for new medicines development. EBiSC has established a robust, reliable supply chain from the generation of cell lines, over the specification, to internationally accepted quality criteria and their world-wide distribution to any qualified user. EBiSC has been developed within a large European public-private partnership project coordinated by Janssen Pharmaceutica and managed by Roslin Cells Sciences Ltd. and which was supported jointly between 2014-2017 by the Innovative Medicines Initiative (IMI) and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA). |
|
|
NEW on 1st March 2019:EBiSC2 – The European Bank for induced pluripotent Stem Cells launches a second project phase to become a self-sustainable repository for human induced pluripotent stem cells (hiPSC), extend the existing cell catalogue, and offer additional hiPSC-related services.EBiSC2 will secure long-term access to well characterised and quality-controlled hiPSCs for academic and commercial researchers worldwide, continuing to support R&D activities such as disease modelling and drug discovery.Read the full EBiSC2 Press Release
|
||